89.3 KPCC: Gov. Brown signs first of its kind drug transparency bill
Pharmaceutical companies selling prescription drugs to Californians will now have to submit information about price increases to the state. The new transparency provisions are part of a new groundbreaking law Gov. Jerry Brown signed Monday morning.
SB 17 requires drug manufacturers to submit their reasoning for price hikes of more than 16 percent over two years. Lawmakers say the new law takes aim at ever increasing health costs.
During a press conference that ended with the governor signing the measure, the bill’s sponsor, Senator Ed Hernandez (D-West Covina) called it one of the most comprehensive bills in the country. The chair of the senate health committee ended his remarks by challenging Washington lawmakers.
"I want to challenge our federal officials to do the same thing at a national level," said Hernandez. "So, that we can make sure that every single person in this country, not only has access to health care, but that they can afford their health care."
The provision in the new law to give 60-days’ notice before raising their price goes into effect at the beginning of 2018. Starting in 2019 the state’s insurance regulators will keep an annual list of the 25 mostly costly drugs, the 25 most commonly prescribed drugs, and which 25 drugs’ prices went up the most.
Hernandez told KPCC Monday the measure is one step forward to help control the continued rise in health care costs. He calls on federal lawmakers to strengthen the federal requirement to require everyone purchase health insurance and other measure to help stabilize the market.
"We have to look at how do we bring more competition," the state senator said.
UCLA health policy professor Stewart Schweitzer believes to the extent SB 17 creates more competition in the drug market, it could work.
"Insurers—for example—can certainly go out and look more aggressively knowing that the price of a particular product is about to go up sharply," he said.
Schweitzer worries the part of the new law that will require the pharmaceutical industry to justify raising the costs of their drugs could be misleading.
"I think it’s not a reasonable step to ask people, 'why are you pricing that so high?'" he said.
The UCLA health economist explains there are too many factors that go into a price to completely answer the question.
"Prices go up because the market is willing to pay that price and that’s true in every single market," said Schweitzer.
To read the rest of the article, click here.